Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial
Not everyone needs comprehensive nutritional testing
The often-cited 10,000-step goal originated from a Japanese marketing campaign for pedometers in the 1960s rather than scientific evidence
The broader Novo obesity estate is concentrated on semaglutide, cagrilintide, amycretin, and the dual-platform portfolio
Importantly, Retatrutide's unique triple receptor agonismtargeting GLP-1, GIP, and glucagon receptorsappears well-tolerated, with adverse events largely consistent with known effects from the broader GLP-1 class, primarily mild gastrointestinal symptoms such as nausea, decreased appetite, and occasional diarrhea, typically resolving within a few weeks of initiation
Targeting 0.8-1.0 grams of protein per pound of goal body weight ensures sufficient intake even as total calories naturally decrease
.png)
